In one study of postmenopausal women, those on hormone therapy experienced greater weight loss with semaglutide than those not on HRT, possibly due to estrogens effects on metabolism and appetite regulation
Pattern 2: The Non-Responder (approximately 15% of switchers) Weight loss plateaus or slows despite escalating to Zepbound 12.5 to 15 mg May report initial response at 5 to 7.5 mg that fades by week 16 to 20 Often have underlying metabolic factors (severe insulin resistance, hypothyroidism, medications causing weight gain) For this group, the switch to tirzepatide does not solve the core problem
GIPR is primarily expressed in pancreatic -cells, adipose tissue, the small intestine, and the central nervous system playing a key role in energy metabolism and nutrient homeostasis
Haas RH, Parikh S, Falk MJ, Saneto RP, Wolf NI, Darin N et al
N., Diehl, F
Semaglutide, the active ingredient in well-known brands out in the market, offers significant benefits as a standalone treatment, focusing on the generic advantages without the brand-specific contexts